BE2016C049I2 - - Google Patents

Info

Publication number
BE2016C049I2
BE2016C049I2 BE2016C049C BE2016C049C BE2016C049I2 BE 2016C049 I2 BE2016C049 I2 BE 2016C049I2 BE 2016C049 C BE2016C049 C BE 2016C049C BE 2016C049 C BE2016C049 C BE 2016C049C BE 2016C049 I2 BE2016C049 I2 BE 2016C049I2
Authority
BE
Belgium
Prior art keywords
pharmaceutical composition
leishmaniasis
proteins
animal
prevention
Prior art date
Application number
BE2016C049C
Other languages
Dutch (nl)
Original Assignee
Laboratorios Leti S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2256124A external-priority patent/CA2256124C/en
Application filed by Laboratorios Leti S L filed Critical Laboratorios Leti S L
Publication of BE2016C049I2 publication Critical patent/BE2016C049I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to a pharmaceutical composition for the prevention and treatment, human or animal, of leishmaniasis. The pharmaceutical composition contains the protein chimera Q, which is the product of a chimeric gene encoding the antigenic determinants of four proteins of Leishmania infantum.
BE2016C049C 1998-12-23 2016-10-06 BE2016C049I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11382598P 1998-12-23 1998-12-23
CA2256124A CA2256124C (en) 1998-12-23 1998-12-23 Chimeric gene formed of the dna sequences that encode the antigenic determinants of four proteins of l. infantum, and protein encoded by said gene, and pharmaceutical composition useful for preventing and/or treating leishmaniosis in animals or humans
PCT/EP1999/010441 WO2000039298A1 (en) 1998-12-23 1999-12-23 Chimeric gene encoding the antigenic determinants of four proteins of l. infantum

Publications (1)

Publication Number Publication Date
BE2016C049I2 true BE2016C049I2 (en) 2019-03-05

Family

ID=25680668

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C049C BE2016C049I2 (en) 1998-12-23 2016-10-06

Country Status (22)

Country Link
EP (1) EP1141305B1 (en)
CN (1) CN1158387C (en)
AT (2) ATE327332T1 (en)
AU (1) AU759316B2 (en)
BE (1) BE2016C049I2 (en)
BG (1) BG65569B1 (en)
BR (1) BRPI9916549B8 (en)
CY (3) CY1105331T1 (en)
CZ (1) CZ20012360A3 (en)
DE (2) DE69931518T2 (en)
DK (1) DK1141305T3 (en)
ES (2) ES2273519T3 (en)
HR (1) HRP20010554A2 (en)
HU (1) HUP0104743A3 (en)
IL (2) IL143956A0 (en)
LU (1) LU93259I2 (en)
MX (1) MXPA01006548A (en)
NL (1) NL300830I2 (en)
PT (2) PT1141305E (en)
SI (1) SI1624063T1 (en)
TR (1) TR200102655T2 (en)
WO (1) WO2000039298A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613337B1 (en) * 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
ES2169995B1 (en) * 2000-04-17 2003-12-01 Leti Lab LIP2A PROTEIN BASED COMPOSITION AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT TO PROVIDE AN IMMUNE RESPONSE AGAINST AN ANTIGEN.
US6673351B1 (en) 2001-03-16 2004-01-06 Astralis, Llc Compositions and methods for the treatment and clinical remission of psoriasis
WO2006058243A2 (en) * 2004-11-24 2006-06-01 Yale University Leishmania antigens and related compositions and uses
CN101977930B (en) * 2008-01-18 2014-12-17 莱蒂实验室私人有限公司 Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant
US8969019B2 (en) * 2009-07-13 2015-03-03 Laboratorios Leti, S.L. Diagnosis of a parasitic disease such as leishmaniasis using ribosomal protein extract (RPE)
SA110310855B1 (en) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal The Use of an l3 and/or l5 Source as a Vaccine or as a Diagnostic for a Parasitic Disease
BR102019003639A2 (en) * 2019-02-22 2021-11-16 Fundação Oswaldo Cruz CHIMERIC PROTEIN, ITS METHOD FOR PRODUCTION AND USE, AS WELL AS NUCLEIC ACID MOLECULE, EXPRESSION CASSETTE, EXPRESSION VECTOR, HOST CELL, COMPOSITION FOR LEISHMANIASIS DIAGNOSIS, LEISHMANIASIS DIAGNOSTIC KIT AND LEISHMANIOSIS INNOVATIVE METHOD
ES2795149B2 (en) 2020-06-08 2022-07-04 Univ Madrid Complutense SYNTHETIC MULTIEPITOPIC CHIMERA AS A VACCINE AND TREATMENT AGAINST LEISHMANIOSIS IN MAMMALS
CN112662694A (en) * 2020-12-25 2021-04-16 康九生物科技(长春)有限公司 Maltose binding protein, maltose binding protein expression vector, recombinant engineering bacteria and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703295A1 (en) * 1994-09-26 1996-03-27 Institut Pasteur Vaccine composition comprising recombinant BCG expressing gp 63 fusion protein
US5912166A (en) * 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
ES2133236B1 (en) * 1997-06-27 2000-04-16 Leti Lab CHEMICAL GENE FORMED BY THE DNA SEQUENCES CODING THE ANTIGENIC DETERMINANTS OF FOUR L. INFANTUM PROTEINS, APPLICABLE FOR THE SEROLOGICAL DIAGNOSIS OF CANINE LEISHMANIOSIS AND OBTAINED PROTEIN.

Also Published As

Publication number Publication date
SI1624063T1 (en) 2009-08-31
CY1105331T1 (en) 2010-03-03
ATE429498T1 (en) 2009-05-15
HUP0104743A3 (en) 2004-10-28
ATE327332T1 (en) 2006-06-15
CZ20012360A3 (en) 2001-10-17
MXPA01006548A (en) 2003-03-27
ES2326174T3 (en) 2009-10-02
PT1624063E (en) 2009-06-19
CN1335889A (en) 2002-02-13
NL300830I1 (en) 2016-09-28
DE69931518T2 (en) 2006-12-21
CY1109221T1 (en) 2014-07-02
AU2434200A (en) 2000-07-31
BRPI9916549B8 (en) 2022-08-30
NL300830I2 (en) 2020-08-31
HRP20010554A2 (en) 2002-08-31
DE69931518D1 (en) 2006-06-29
ES2273519T3 (en) 2007-05-01
EP1141305A1 (en) 2001-10-10
WO2000039298A1 (en) 2000-07-06
DK1141305T3 (en) 2006-09-25
PT1141305E (en) 2006-10-31
IL143956A0 (en) 2002-04-21
BRPI9916549B1 (en) 2018-10-02
TR200102655T2 (en) 2002-04-22
CN1158387C (en) 2004-07-21
CY2016033I2 (en) 2017-03-15
CY2016033I1 (en) 2017-03-15
DE69940793D1 (en) 2009-06-04
EP1141305B1 (en) 2006-05-24
AU759316B2 (en) 2003-04-10
LU93259I2 (en) 2016-12-06
BG105725A (en) 2002-06-28
BR9916549A (en) 2005-01-04
HUP0104743A2 (en) 2002-03-28
IL143956A (en) 2010-11-30
BG65569B1 (en) 2008-12-30

Similar Documents

Publication Publication Date Title
BE2016C049I2 (en)
PT910647E (en) Human dnase i hyperactive variants
WO2000053758A3 (en) Compositions and methods for the treatment of immune related diseases
ATE348113T1 (en) RECOMBINANT ANTI-CD4 ANTIBODY FOR HUMAN TREATMENT
WO2000073452A3 (en) Compositions and methods for the treatment of immune related diseases
PT2009025E (en) Method of inhibiting osteoclast activity
BG104266A (en) Aminoterminally incised mcp-2 as haemokin antagonists
MXPA02010458A (en) Thrombopoietin receptor modulating peptide.
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
ATE310828T1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF ACQUIRED DISEASES
WO2001095946A3 (en) Combination product for carrying out a cytotoxic treatment in a mammal
MXPA04001986A (en) Compositions and methods for the treatment of immune related diseases.
YU51601A (en) Chimeric gene encoding the antigenic determinants of four proteins of l.infantum
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
DE59410423D1 (en) SERIN-THREONINE-KINASE CONTAINING TUMOR THERAPY AND TUMOR DIAGNOSIS
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001016319A3 (en) Compositions and methods for the treatment of immune related diseases
ATE213637T1 (en) COMPOSITIONS CONTAINING BISMUTH FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISEASES
DE60143025D1 (en) COMPOSITION FOR THE TREATMENT OF PERIODONTAL DISEASES
EP1624063A3 (en) Chimeric gene encoding the antigenic determinants of four proteins of L. infantum
MX9800686A (en) Novel protein hmw human mp52
EP1529842A3 (en) Compositions and methods for the treatment of immune related diseases